GlassScriptPhysician profile
Muhammad A Khan
NPI 1316120660
$4,822.32
in general payments reported to CMS, 2019-2025
22 companies · $926 in 2025
The $926 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $397 · 2021: $366 · 2022: $722 · 2023: $1,021 · 2024: $748 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,569 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.75 |
| Education | $126.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $812.99 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $554.62 | 2020-2023 | Krystexxa |
| Amgen INC. | $544.15 | 2020-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $524.35 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $409.32 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $356.77 | 2019-2024 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $299.07 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $231.12 | 2020-2025 | Filspari |
| Vifor Pharma, INC. | $223.49 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $169.46 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $133.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.48 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $95.06 | 2021-2025 | |
| Akebia Therapeutics INC | $67.34 | 2020-2022 | |
| Ardelyx, INC. | $62.06 | 2025 | Ibsrela |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $61.96 | 2025 | |
| Lilly USA, LLC | $57.92 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $37.62 | 2022 | |
| Calliditas Therapeutics US INC. | $24.89 | 2025 | Tarpeyo |
| Arbor Pharmaceuticals, INC. | $20.12 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.